Is There a Wegovy Shortage Right Now, and What Does It Mean for You?

The biggest misconception: a shortage means Wegovy is unavailable everywhere

When people hear that Wegovy is in short supply, the assumption is often that all doses, across all pharmacies, have simply run out. That is rarely true. Shortages in the UK have tended to be uneven, particular strengths at particular moments, rather than a blanket absence. During 2023 and into 2024, demand from people newly prescribed Wegovy outpaced what Novo Nordisk had planned for, and certain dose steps became genuinely difficult to source. By late 2025 and into 2026, supply had become more reliable at the standard 2.4mg maintenance dose, though availability of the newer 7.2mg pen remained limited as the format was only approved by the MHRA in April 2026.

The practical consequence of this dose-by-dose picture is that a pharmacy running low on 1.7mg pens might still have 1.0mg or 2.4mg. That is not a solution, titrating incorrectly, or staying at a lower dose without clinical reason, is a decision that belongs with your prescriber, not with whoever has stock. If you want to understand more about the dose steps and what each represents, this guide to Wegovy's dose levels sets it out clearly.

The NHS medicines shortage notice system and Novo Nordisk's own supply communications are the authoritative sources here. Rumour and social media tend to magnify scarcity, and create demand spikes that can briefly worsen the very shortages they describe.

Why shortages happen: demand, manufacturing capacity and a medicine that takes time to make

GLP-1 medicines are biologics, manufactured through a process that cannot simply be scaled up overnight. Novo Nordisk has invested billions in expanding production capacity globally, and Wegovy's availability in the UK has reflected that ramp-up: early launch (2023) coincided with a period when global demand, led by the US market, was already straining supply chains. The UK was, in some respects, joining a queue.

Prescription volumes have grown steadily as awareness rises and as the NICE recommendation for semaglutide under TA875 means more NHS specialist services can prescribe it. Private prescriptions add further demand on top. Meanwhile, Ozempic (the same semaglutide molecule but licensed for type 2 diabetes) has its own supply pressures, and disruptions there have occasionally rippled into Wegovy stock too, even though the two products are dispensed separately.

There is also a timing effect that pharmacies quietly absorb: orders placed around bank holidays, month-end payday surges or the start of a new year tend to cluster, creating temporary local shortages even when national supply is adequate. A prescription submitted on the Tuesday after a long weekend may sit in a different supply environment from one submitted mid-month.

Understanding the current Wegovy supply position in more detail can help you plan ahead rather than scramble.

What to do if you cannot get your next Wegovy pen

Missing a dose or delaying a pen because of a supply gap is more common than prescribers would like. The NHS guidance on weight-management injections is clear that decisions about what to do (whether that means staying at your current dose, pausing, or considering an alternative) should be made with your prescriber, not independently. Some people restart Wegovy after a short break without any significant problem; others experience a return of appetite or nausea on restarting. Neither outcome can be predicted in advance.

A note on timing: if you know you will be away, or that your usual order window falls across a public holiday, flagging this early with your pharmacy gives them the best chance of having stock prepared. Last-minute requests when supply is already stretched are harder to fulfil.

The one response that is not safe is sourcing semaglutide pens from an unverified seller to fill a gap. The MHRA has repeatedly warned about counterfeit pens circulating online and through social media. Fake pens in UK enforcement operations have been found to contain insulin rather than semaglutide, a substitution that can cause serious harm. Any seller offering these medicines without asking for a prescription is a red flag, not a convenience. You can verify any online pharmacy on the GPhC register in seconds.

Where Wegovy supply stands now, and what it means for starting treatment

For people already on Wegovy, the key priority is continuity under clinical supervision. For people thinking about starting, the supply picture is genuinely more stable than it was at launch, though it would be misleading to say stock is universally guaranteed at every dose. This is one reason a same-day clinical review by a real prescriber matters: at nume, every consultation is read by a GPhC-registered Independent Prescriber who can assess suitability and advise on the current picture, not a scoring algorithm that approves in the abstract.

If you are weighing up Wegovy against other licensed options, there is useful context on how semaglutide works and on the treatment options available more broadly. For those curious about how quickly results typically appear once treatment is underway, this page on when Wegovy starts working covers what the evidence shows.

Cost is a separate consideration from availability, and the Wegovy cost page sets out the honest private pricing context without the small print many providers bury. When you are ready to talk through whether Wegovy is appropriate for you, starting a free consultation is the natural next step.